Highlights Shanghai Henlius Biotech, Inc. OTC Markets

Equities

SGBCF

CNE100003N76

Delayed OTC Markets Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		-.--%	-.--%

Apr. 26	Shanghai Henlius Biotech's Cancer Drug Gets the Nod from US FDA	MT
Apr. 24	Shanghai Henlius Biotech Doses 1st Patient in Fibrosis Drug Clinical Study in China	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Shanghai Henlius Biotech, Inc. Announces First Subject Dosed in Phase 1 Clinical Study in Healthy Subjects of HLX6018 in Mainland China	Apr. 23	CI
Henlius Biotech Gets Clearance for China Clinical Trial of Carcinoma Drug	Apr. 17	MT
Shanghai Henlius Biotech, Inc. Announces Application for the Clinical Trial of HLX53 (Anti-TIGIT Fc Fusion Protein) in Combination with HANSIZHUANG (Serplulimab Injection) and HANBEITAI (Bevacizumab Injection) for the First-Line Treatment of Local Advanced or Metastatic Hepatocellular Carcinoma was Approved by the National Medical Products Administration	Apr. 17	CI
Shanghai Henlius Biotech Denosumab Biosimilar HLX14 Meets Endpoint	Apr. 08	MT
Shanghai Henlius Biotech, Inc Announces Phase 3 Comparative Clinical Study of Prolia® and Xgeva® Biosimilar Candidate HLX14 Met Primary Endpoints	Apr. 08	CI
Phase 3 Trial of Shanghai Henlius Biotech’s Osteoporosis Drug Meets Primary Study Endpoints	Apr. 05	MT
Shanghai Henlius Biotech, Inc. Announces International Multi-Centre Phase 3 Clinical Study of Biosimilar of Denosumab HLX14 for Treatment of Osteoporosis in Postmenopausal Women at High Risk for Fracture has Met Primary Study Endpoints	Apr. 05	CI
Shanghai Henlius Biotech Turns to Profit in 2023	Mar. 22	MT
Shanghai Henlius Biotech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 21	CI
Shanghai Henlius Biotech, Inc. Announces the First Patient Has Been Dosed in A Phase 1 Clinical Study of Hlx42 for Injection	Mar. 14	CI
Shanghai Henlius Biotech, Inc. Announces Application for Clinical Trial of HLX6018 (Recombinant Anti-GARP/TGF-1 Humanised Monoclonal Antibody Injection) Approved by the National Medical Products Administration	Mar. 12	CI
Shanghai Henlius Biotech Expects Record Full-Year Profit	Mar. 05	MT
Shanghai Henlius Biotech, Inc. Provides Unaudited Consolidated Earnings Guidance for the Year Ended December 31, 2023	Mar. 04	CI
Shanghai Henlius Biotech, Inc. Announces Supplemental New Drug Applications of HANDAYUAN (Adalimumab Injection) for the New Indications Have Been Accepted by the National Medical Products Administration	Feb. 29	CI
Shanghai Henlius Biotech, Inc. Announces Phase 1 Clinical Study of A Biosimilar of Denosumab HLX14 Successfully Completed	Feb. 01	CI
Sermonix Pharmaceuticals Inc. and Shanghai Henlius Biotech, Inc. Announce Strategic Collaboration and Exclusive License Agreements for Novel Endocrine Therapy Lasofoxifene	Jan. 10	CI
Indonesia Grants Marketing Approval to Henlius Biotech's Small-Cell Lung Cancer Treatment	Dec. 29	MT
Shanghai Henlius Biotech, Inc. Receives Fast Track Designation by the United States Food and Drug Administration	Dec. 27	CI
Shanghai Henlius Biotech, Inc. Announces Dosing of First Subject in A Phase 1 Clinical Studyin Healthy Chinese Male Subjects of Ipilimumab Biosimilarhlx13 (Recombinant Anti-Ctla-4 Fully Human Monoclonalantibody Injection)	Dec. 13	CI
China Accepts Henlius Application for New Indication of Cancer Drug	Dec. 12	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Shanghai Henlius Biotech, Inc. OTC Markets

Equities

SGBCF

CNE100003N76

Highlights

Filters